Bringing Mohammad to the mountain: New strategies for intravitreal therapy service delivery
Corresponding Author
Fred K. Chen PhD, FRANZCO
Centre for Ophthalmology and Visual Science (Lions Eye Institute), The University of Western Australia, Nedlands, Western Australia, Australia
Ophthalmology, Department of Surgery, University of Melbourne, Melbourne, Victoria, Australia
Royal Victorian Eye and Ear Hospital, Melbourne, Victoria, Australia
Correspondence
Fred K. Chen, Centre for Ophthalmology and Visual Science (Lions Eye Institute), The University of Western Australia, Nedlands, WA, Australia.
Email: [email protected]
Search for more papers by this authorRachael C. Heath Jeffery MPH, MChD
Centre for Ophthalmology and Visual Science (Lions Eye Institute), The University of Western Australia, Nedlands, Western Australia, Australia
Royal Victorian Eye and Ear Hospital, Melbourne, Victoria, Australia
Search for more papers by this authorAdrian T. Fung MMed, FRANZCO
Westmead Clinical School, Discipline of Ophthalmology and Eye Health, The University of Sydney, Sydney, New South Wales, Australia
Save Sight Institute, Central Clinical School, Discipline of Ophthalmology and Eye Health, The University of Sydney, Sydney, New South Wales, Australia
Department of Ophthalmology, Faculty of Medicine, Health and Human Sciences, Macquarie University Hospital, Sydney, New South Wales, Australia
Search for more papers by this authorCorresponding Author
Fred K. Chen PhD, FRANZCO
Centre for Ophthalmology and Visual Science (Lions Eye Institute), The University of Western Australia, Nedlands, Western Australia, Australia
Ophthalmology, Department of Surgery, University of Melbourne, Melbourne, Victoria, Australia
Royal Victorian Eye and Ear Hospital, Melbourne, Victoria, Australia
Correspondence
Fred K. Chen, Centre for Ophthalmology and Visual Science (Lions Eye Institute), The University of Western Australia, Nedlands, WA, Australia.
Email: [email protected]
Search for more papers by this authorRachael C. Heath Jeffery MPH, MChD
Centre for Ophthalmology and Visual Science (Lions Eye Institute), The University of Western Australia, Nedlands, Western Australia, Australia
Royal Victorian Eye and Ear Hospital, Melbourne, Victoria, Australia
Search for more papers by this authorAdrian T. Fung MMed, FRANZCO
Westmead Clinical School, Discipline of Ophthalmology and Eye Health, The University of Sydney, Sydney, New South Wales, Australia
Save Sight Institute, Central Clinical School, Discipline of Ophthalmology and Eye Health, The University of Sydney, Sydney, New South Wales, Australia
Department of Ophthalmology, Faculty of Medicine, Health and Human Sciences, Macquarie University Hospital, Sydney, New South Wales, Australia
Search for more papers by this authorCONFLICT OF INTEREST STATEMENT
Fred K. Chen: Received research grant from Bayer, speaker and consulting fees from Novartis, Roche, Apellis and PYC Therapeutics. Adrian T. Fung: Alcon (lecture honoraria, advisory board, travel fees, research), Roche (consultant, lecture honoraria, advisory board, travel fees, research), Bayer (consultant, lecture honoraria, advisory board, travel fees, research), Novartis (lecture honoraria, travel), Apellis (advisory board), Astellas (advisory board), Abbvie (lecture honoraria, travel fees, research), Ionis Pharmaceuticals (research), Opthea (equity). Rachael C. Heath Jeffery: None.
REFERENCES
- 1Fung AT. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration in 2022: same, same but different. Clin Exp Ophthalmol. 2022; 50(3): 270-273.
- 2Yuen YS, Gilhotra JS, Dalton M, et al. Diabetic macular oedema guidelines: an Australian perspective. J Ophthalmol. 2023; 2023:6329819. doi:10.1155/2023/6329819
- 3Cornish EE, Zagora SL, Spooner K, Fraser-Bell S. Management of macular oedema due to retinal vein occlusion: an evidence-based systematic review and meta-analysis. Clin Exp Ophthalmol. 2023; 51(4): 313-338.
- 4http://medicarestatistics.humanservices.gov.au/statistics/ Accessed September 28, 2024
- 5Khanani AM, Kotecha A, Chan A, et al. TENAYA and LUCERNE: two-year results from the phase 3 neovascular age-related macular degeneration trials of faricimab with treat- and-extend dosing in year 2. Ophthalmology. 2024; 131(8): 914-926.
- 6Wong TY, Haskova Z, Asik K, et al. Faricimab treat-and extend for diabetic macular edema: two-year results from the ramdomized phase 3 YOSEMITE and RHINE trials. Ophthalmology. 2024; 131(6): 708-723.
- 7Rosenberg D, Deonarain DM, Gould J, et al. Efficacy, safety, and treatment burden of treat-and-extend versus alternative anti-VEGF regimens for nAMD: a systematic review and meta-analysis. Eye. 2023; 37: 6-16.
- 8Sarohia GS, Nanji K, Khan M, et al. Treat-and-extend versus alternate dosing strategies with anti-vascular endothelial growth factor agents to treat center involving diabetic macular edema: a systematic review and meta-analysis of 2,346 eyes. Surv Ophthalmol. 2022; 67(5): 1346-1363.
- 9Regillo C, Berger B, Brooks L, et al. Archway phase 3 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration 2-year results. Ophthalmology. 2023; 130(7): 735-747.
- 10Eichenbaum DA, Freeman WR, Chang MA, et al. Endophthalmitis in eyes treated with the port delivery system with ranibizumab: summary of cases during clinical trial development. Ophthalmol Retina. 2024; S2468-6530(24): 363-368. Online ahead of print.
- 11Campochiaro PA, Avery R, Brown DM, et al. Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1/2a dose-escalation study. Lancet. 2024; 403(10436): 1563-1573.
- 12Buckley T, MacLaren RE, Kapetanovic JC. Meta-analysis of gene therapy associated uveitis (GTAU). Invest Ophthalmol vis Sci. 2024; 65: 5312.
- 13Amoaku W, Bailey C, Downey L, et al. Providing a safe and effective intravitreal treatment service: strategies for service delivery. Clin Ophthalmol. 2020; 14: 1315-1328.
- 14Lee JCC, Razavi H, Nejatian MM, Drinkwater J, Turner AW. Endophthalmitis following intravitreal injections administered by junior medical officers in rural Western Australia. Clin Exp Ophthalmol. 2024; 52(8): 853-860.
- 15Lee MK, Mehta D, Welch SH, Gajus M, Gale J, Sandhu SS. The range of intravitreal injection practices in Australia and New Zealand. Clin Exp Ophthalmol. 2023; 51(8): 868-870.
- 16Chandra P, Welch S, Oliver GF, Gale J. The carbon footprint of intravitreal injections. Clin Exp Ophthalmol. 2022; 50(3): 347-349.
- 17Rogerson T, Dedina L, Goggin M, Chan WO. Salvageable waste associated with intravitreal injections: a local medical waste management approach. Clin Exp Ophthalmol. 2022; 51(1): 31-35.
- 18Lau PET, Jenkins KS, Layton CJ. Current evidence for the prevention of endophthalmitis in anti-VEGF intravitreal injections. J Ophthalmol. 2018; 2018:8567912.
- 19Lam D, Susith K, Kim L, Wijesinghe N, Tharmalingam M. 'Closing the gap' on visual acuity outcomes of indigenous and remote patients receiving intravitreal injections in northern Australia. Clin Exp Ophthalmol. 2023; 51(2): 170-172.
- 20Wang N, Hunt A, Nguyen V, et al. One-year real-world outcomes of bevacizumab for the treatment of macular oedema secondary to retinal vein occlusion. Clin Exp Ophthalmol. 2022; 50(9): 1038-1046.
- 21Verbraak FD, Ponsioen DL, Tigchelaar-Besling OAM, et al. Real-world treatment outcomes of neovascular age-related macular degeneration in The Netherlands. Acta Ophthalmol. 2021; 99(6): e884-e892.
- 22Meyer J, Carly F, Turner AW, Hessom R. Intravitreal dexamethasone versus bevacizumab in aboriginal and Torres Strait islander patients with diabetic macular oedema: the OASIS study (a randomised control trial). Clin Exp Ophthalmol. 2022; 50(5): 522-533.
- 23Kenworthy MK, Alexis JA, Ramakrishnan P, Chen FK. Retreatment interval lengthening achieved in two thirds of eyes with prolonged intensive anti-VEGF therapy for neovascular age-related macular degeneration after switching to faricimab. Clin Exp Ophthalmol. 2023; 52(5): 589-591.
- 24Chen K-J, Wu W-C, Chen Y-P, Liu L. Intravenous drug use-related endophthalmitis. Clin Exp Ophthalmol. 2022; 50(5): 575-578.
- 25Fan Gaskin JC, Wang BZ, Toalster N, Ang GS. Risk factors associated with XEN gel stent-related endophthalmitis. Clin Exp Ophthalmol. 2022; 50(6): 683-684.
- 26Hou C-H, Lee J-S, Lin K-K, Peng W-S, Pu C, See L-C. Risk and dose-response relationship of diabetes mellitus for endophthalmitis after cataract surgery in a nationwide cohort study in Taiwan. Clin Exp Ophthalmol. 2023; 51(7): 692-703.
- 27VanderBeek BL, Chen Y, Tomaiuolo M, et al. Endophthalmitis rates and types of treatments after intraocular procedures. JAMA Ophthlamol. 2024; 142(9): 827-834.
- 28Michael E, Welch S, Niederer RL. Rapid treatment of endophthalmitis with intravitreal antibiotics is associated with better vision outcomes. Clin Exp Ophthalmol. 2022; 51(2): 137-143.
- 29Welch S, Bhikoo R, Wang N, et al. Better visual outcome associated with early vitrectomy in the management of endophthalmitis. Br J Ophthalmol. 2022; 106(8): 1145-1149.
